Silver Spring, Md. – June 20, 2019 – Aziyo Biologics, Inc., a fully integrated regenerative medicine company, announced today it has signed an exclusive, multi-year distribution agreement with Medtronic for the U.S. orthopedic market. Per the agreement, Aziyo will manufacture and supply FiberCel to Medtronic for distribution through the company’s sales and marketing organization.
FiberCel is a bone repair product made from human tissue utilizing Aziyo’s long standing bone repair matrix manufacturing expertise. Engineered to be like natural tissue, FiberCel provides improved handling properties critical for use as a bone void filler in various orthopedic procedures. The product contains cancellous bone particles with preserved living cells and demineralized cortical bone fibers combined using Aziyo’s proprietary manufacturing processes to create a unique and innovative solution. FiberCel is another example of Aziyo’s commitment to preserve the natural properties of their orthopedic regenerative tissue products portfolio through cell health preservation and bone fiber optimization techniques.
“As we continue to develop novel products for orthopedic medicine, we are thrilled to partner with a recognized leader like Medtronic to help us bring FiberCel to market,” said Ron Lloyd, President and Chief Executive Officer, Aziyo Biologics. “This partnership combines Aziyo’s biologic expertise with Medtronic’s demonstrated ability to commercialize and distribute innovative orthopedic solutions for surgeons and their patients.”
FiberCel is a next generation viable bone matrix allograft designed to perform and handle more like high quality autograft. Aziyo’s proprietary manufacturing process is designed to optimally protect the tissue environment with less disruption. FiberCel is based on science that brings bone grafting closer to meeting the surgeon and patient’s needs and provides a better option for bone repair. To request information about FiberCel, do so via the Aziyo website.